IRIS
CAVALLI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.111
NA - Nord America 1.489
EU - Europa 1.140
SA - Sud America 614
AF - Africa 44
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 5.402
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.420
SG - Singapore 864
CN - Cina 614
BR - Brasile 510
SE - Svezia 404
HK - Hong Kong 315
IT - Italia 212
VN - Vietnam 174
DE - Germania 147
RU - Federazione Russa 107
FI - Finlandia 64
GB - Regno Unito 59
AR - Argentina 48
CA - Canada 40
IN - India 28
FR - Francia 26
ZA - Sudafrica 25
AT - Austria 24
PL - Polonia 23
EC - Ecuador 22
MX - Messico 20
IE - Irlanda 17
JP - Giappone 17
NL - Olanda 17
IQ - Iraq 16
ID - Indonesia 15
ES - Italia 13
BD - Bangladesh 12
TR - Turchia 11
CO - Colombia 10
MA - Marocco 8
PK - Pakistan 8
PY - Paraguay 8
VE - Venezuela 7
AZ - Azerbaigian 5
CL - Cile 5
UA - Ucraina 5
UZ - Uzbekistan 5
BG - Bulgaria 4
IR - Iran 4
PE - Perù 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
IL - Israele 3
KE - Kenya 3
TN - Tunisia 3
TW - Taiwan 3
BE - Belgio 2
EG - Egitto 2
EU - Europa 2
JO - Giordania 2
LT - Lituania 2
NO - Norvegia 2
NP - Nepal 2
RO - Romania 2
SV - El Salvador 2
AL - Albania 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
MD - Moldavia 1
ME - Montenegro 1
OM - Oman 1
PA - Panama 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.402
Salva come PNG Salva come JPEG
Città #
Singapore 351
Hong Kong 313
Dallas 285
Ashburn 187
Shanghai 170
Hefei 119
Lawrence 107
Princeton 107
New York 87
Beijing 82
Ho Chi Minh City 72
Milan 65
Los Angeles 57
Munich 52
Boardman 42
São Paulo 41
Moscow 39
Hanoi 35
Nuremberg 31
Helsinki 30
Turku 23
Rio de Janeiro 21
Denver 20
Guangzhou 19
Atlanta 18
Cesano Boscone 17
Dublin 17
Montreal 17
Poplar 17
Warsaw 17
Seattle 16
Johannesburg 15
Rome 13
Tokyo 13
Brooklyn 12
Chicago 12
London 12
Stockholm 12
Brasília 10
Houston 10
Lappeenranta 10
Santa Clara 10
Ankara 8
Belo Horizonte 8
Chennai 8
Curitiba 8
Frankfurt am Main 8
Orem 8
The Dalles 8
Toronto 8
Vienna 8
Amsterdam 7
Porto Alegre 7
Bologna 6
Buenos Aires 6
Falkenstein 6
Guayaquil 6
Haiphong 6
Manchester 6
Mexico City 6
Pune 6
Querétaro 6
Salvador 6
Xi'an 6
Baku 5
Bauru 5
Campinas 5
Can Tho 5
Cape Town 5
Hải Dương 5
Jakarta 5
Jiaxing 5
Mumbai 5
Quito 5
Saint Louis 5
Thái Bình 5
Tianjin 5
Uberlândia 5
Verona 5
Vitória 5
Wolfhagen 5
Baghdad 4
Biên Hòa 4
Boston 4
Brescia 4
Buffalo 4
Da Nang 4
Fortaleza 4
Londrina 4
Mestrino 4
Osasco 4
Phoenix 4
Quezon City 4
Rio Claro 4
San Francisco 4
Sorocaba 4
São Bernardo do Campo 4
Tashkent 4
Vancouver 4
Alessandria 3
Totale 2.915
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 132
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 109
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 107
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 95
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis 91
A bitter effect: thrombocytopenia induced by a quinidine-containing beverage 85
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 85
A Novel Histiocytosis With Synovial and Skin Involvement 82
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 76
3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target 76
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 74
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 73
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 72
Advances in potential targeted therapies for Erdheim-Chester disease 71
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies 71
Testosterone in males with COVID-19: A twelve-month cohort study 70
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 67
A virus-free cellular model recapitulates several features of severe COVID-19 67
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 66
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 66
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 66
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 65
Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients 65
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 64
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 64
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis 62
Current treatment options and safety considerations when treating adult-onset Still’s disease 61
Anakinra for COVID-19: how to interpret elevations in serum liver enzymes 60
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 59
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 59
Autoimmune vitiligo is associated with gain-offunction by a transcriptional regulator that elevates expression of HLA-A∗02:01 in vivo 58
Autophagy and Protein Secretion 58
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. 57
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 57
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis 57
Anakinra therapy for non-cancer inflammatory diseases 56
An enlightening scan 56
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura 55
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 53
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout 53
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 53
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 52
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial 52
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis 51
ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE 48
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies 47
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 47
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease 46
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 46
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 46
Anakinra for patients with COVID-19 – Authors' reply 46
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 45
Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case 43
Testosterone in males with COVID-19: A 7-month cohort study 43
Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure 42
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 42
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 42
Treating Pulmonary Silicosis by Blocking Interleukin 1 41
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance 41
Myocarditis: An Interleukin-1-Mediated Disease? 41
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab 40
Charcot's arthropathy of the spine 40
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients 40
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity 40
Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness 40
Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation 39
Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance 39
Priorities of biomedical research 38
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 37
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease 37
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 36
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 36
Diagnosing Erdheim-Chester disease 36
Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease 35
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 35
Letter by Campochiaro et al regarding article, “Clinical features, management, and outcomes of immune checkpoint inhibitor–Related cardiotoxicity” 35
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 35
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 35
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses 35
Efficacy and safety of biological agents in adult-onset Still's disease 34
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. 34
Tocilizumab in patients with multisystem Erdheim–Chester disease 34
Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis 34
Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis 34
Publications are not the finish line: Focusing on societal rather than publication impact 34
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease (Arthritis Research and Therapy (2019) 21 (54) DOI: 10.1186/s13075-019-1843-9) 34
Suppression of inflammation and acquired immunity by IL-37 34
Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9) 33
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo 33
Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer 33
Charcot's arthropathy of the hip 33
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome 33
CARDIAC CINE MRI IN ERDHEIM-CHESTER DISEASE: DATA FROM A LARGE ITALIAN COHORT 32
Orthopnea with platydeoxia secondary to prominent Eustachian valve 32
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 32
Prevalence of Takayasu arteritis in young women with acute ischemic heart disease 32
Treating Life-Threatening Myocarditis by Blocking Interleukin-1 32
CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT 31
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease 31
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 31
Totale 5.132
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.114
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.114
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202138 0 0 0 0 0 12 9 3 2 4 6 2
2021/2022128 1 0 32 31 11 11 4 2 21 3 8 4
2022/2023678 240 157 53 5 12 81 27 52 33 2 8 8
2023/2024496 17 40 60 43 48 72 23 52 5 8 40 88
2024/20251.782 179 31 37 51 67 122 197 221 346 232 134 165
2025/20262.416 345 390 410 786 388 97 0 0 0 0 0 0
Totale 5.633